Diagonal Bio AB (DIABIO) - Net Assets
Based on the latest financial reports, Diagonal Bio AB (DIABIO) has net assets worth Skr26.97 Million SEK (≈ $2.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr29.10 Million ≈ $3.13 Million USD) and total liabilities (Skr2.13 Million ≈ $229.54K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Diagonal Bio AB (DIABIO) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr26.97 Million |
| % of Total Assets | 92.67% |
| Annual Growth Rate | 28.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 126.19 |
Diagonal Bio AB - Net Assets Trend (2020–2024)
This chart illustrates how Diagonal Bio AB's net assets have evolved over time, based on quarterly financial data. Also explore Diagonal Bio AB (DIABIO) total assets for the complete picture of this company's asset base.
Annual Net Assets for Diagonal Bio AB (2020–2024)
The table below shows the annual net assets of Diagonal Bio AB from 2020 to 2024. For live valuation and market cap data, see market cap of Diagonal Bio AB.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr24.59 Million ≈ $2.65 Million |
+15.75% |
| 2023-12-31 | Skr21.25 Million ≈ $2.29 Million |
-32.01% |
| 2022-12-31 | Skr31.25 Million ≈ $3.36 Million |
-7.72% |
| 2021-12-31 | Skr33.87 Million ≈ $3.64 Million |
+280.81% |
| 2020-12-31 | Skr8.89 Million ≈ $957.03K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diagonal Bio AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4645300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr4.00 Million | 16.26% |
| Other Components | Skr73.61 Million | 299.30% |
| Total Equity | Skr24.59 Million | 100.00% |
Diagonal Bio AB Competitors by Market Cap
The table below lists competitors of Diagonal Bio AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Logistics Development Group PLC
LSE:LDG
|
$704.91K |
|
Volvere PLC
LSE:VLE
|
$709.32K |
|
Thunder Power Holdings, Inc.
NASDAQ:AIEV
|
$710.14K |
|
SDM SE
XETRA:75S
|
$711.13K |
|
Darmi Bersaudara Tbk PT
JK:KAYU
|
$701.39K |
|
Watkin Jones PLC
LSE:WJG
|
$700.61K |
|
Alternative Income REIT PLC
LSE:AIRE
|
$700.31K |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
$699.50K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagonal Bio AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,247,000 to 24,594,000, a change of 3,347,000 (15.8%).
- Net loss of 9,930,000 reduced equity.
- New share issuances of 13,277,000 increased equity.
- Other comprehensive income decreased equity by 23,754,000.
- Other factors increased equity by 23,754,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-9.93 Million | -40.38% |
| Share Issuances | Skr13.28 Million | +53.98% |
| Other Comprehensive Income | Skr-23.75 Million | -96.58% |
| Other Changes | Skr23.75 Million | +96.58% |
| Total Change | Skr- | 15.75% |
Book Value vs Market Value Analysis
This analysis compares Diagonal Bio AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Skr2.54 | Skr0.00 | x |
| 2021-12-31 | Skr2.90 | Skr0.00 | x |
| 2022-12-31 | Skr3.29 | Skr0.00 | x |
| 2023-12-31 | Skr0.58 | Skr0.00 | x |
| 2024-12-31 | Skr0.09 | Skr0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagonal Bio AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16016.13%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-40.38%) is below the historical average (-37.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -6.56% | -2872.28% | 0.00x | 1.12x | Skr-1.47 Million |
| 2021 | -34.44% | -2865.60% | 0.01x | 1.06x | Skr-15.05 Million |
| 2022 | -51.72% | -7962.56% | 0.01x | 1.09x | Skr-19.29 Million |
| 2023 | -54.96% | -50773.91% | 0.00x | 1.34x | Skr-13.80 Million |
| 2024 | -40.38% | -16016.13% | 0.00x | 1.10x | Skr-12.39 Million |
Industry Comparison
This section compares Diagonal Bio AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagonal Bio AB (DIABIO) | Skr26.97 Million | -6.56% | 0.08x | $703.53K |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more